VRX - Valeant Pharmaceuticals International, Inc.
| Previous Close | 24.23 |
| Open | 24.15 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 2900 |
| Day's Range | 23.36 - 24.43 |
| 52 Week Range | 10.94 - 27.79 |
| Volume | 6,571,593 |
| Avg. Volume | 8,208,334 |
| Market Cap | 8.174B |
| Beta | -0.93 |
| PE Ratio (TTM) | 3.43 |
| EPS (TTM) | 6.83 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2010-11-10 |
| 1y Target Est | 23.25 |
- CNBC Videos•6 days ago
Valeant changes name to Bausch Health Companies, CEO expl...
Bausch Health Companies, formerly known as Valeant Pharmaceutical International Inc., began trading under its new name today. CEO Joseph Papa discusses the new name and what other changes were made in an exclusive interview.
- Fortune Videos•27 days ago
Cindy Eckert Is Back As CEO of Sprout Pharmaceuticals
Eckert stopped by Fortune to talk about her "real launch" of Sprout's Addyi after getting it back from Valeant Pharmaceuticals.
- Motley Fool•3 days ago
Why Bausch Health Companies Stock Has Gained Nearly 12% Halfway Through 2018
A strong first-quarter sent the pharmaceutical company's shares northward, but this positive momentum is starting to fade after a key regulatory setback.
Market Realist•6 days agoValeant Pharmaceuticals before Its Q2 2018 Earnings
Valeant Pharmaceuticals (VRX), now known as Bausch Health Companies (BHC), generated revenues of $2 billion in the first quarter compared to $2.1 billion in the first quarter of 2017, reflecting a 5% YoY (year-over-year) decline.
Market Realist•6 days agoAnalyst Recommendations for Valeant Pharmaceuticals in July
In July, the FDA accepted Bausch + Lomb’s NDA (New Drug Application) for sub-micron loteprednol etabonate for the treatment of patients who have undergone ocular surgery and are showing symptoms of post-operative inflammation and pain.
- Zacks•6 days ago
Implied Volatility Surging for Valeant Pharmaceuticals (VRX) Stock Options
Investors in Valeant Pharmaceuticals (VRX) need to pay close attention to the stock based on moves in the options market lately.
- InvestorPlace•10 days ago
3 Real Risks That Could Make You Reconsider Buying Celgene Stock
Celgene Corporation (NASDAQ:CELG) stock looks attractive here, for a number of reasons. Celgene stock has sold off, losing about 43% of its value. Celgene touched a four-year low in May before a recent rebound. The decline leaves Celgene looking awfully cheap, at a little over 8.3x 2019 consensus EPS estimates.
- PR Newswire•13 days ago
Bausch + Lomb Announces U.S. FDA Filing Acceptance For Loteprednol Etabonate Ophthalmic Gel, 0.38%
PDUFA Date Set for February 25, 2019 LAVAL, Quebec , July 9, 2018 /PRNewswire/ -- – Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International, ...
- InvestorPlace•16 days ago
5 Pharmaceutical and Biotech Stocks to Consider for July
On July 3, the Financial Times reported that Pfizer Inc. (NYSE:PFE) is increasing the prices of 100 of its drugs by around 10 percent. Value investors looking to buy in should stick with drug stocks trading at favorable valuations and whose business faces multiple positive catalysts ahead. Here are 5 biotech stocks to get you started for July.
Markit•19 days agoSee what the IHS Markit Score report has to say about Valeant Pharmaceuticals International Inc.
Valeant Pharmaceuticals International Inc NYSE:VRX
- MarketWatch•21 days ago
Valeant is back on to its old drug-pricing ways
A controversy over massive price increases, along with other scandals, wrecked Valeant Pharmaceutical International Inc.’s reputation as well as its stock price in recent years. Valeant (VRX) is using two techniques to raise prices on one of its best-selling drugs: it has increased the size of the package of its diarrhea medication, called Xifaxan, by 43%, from 42 pills to 60, and it is charging about 6% more per milligram, according to an analyst note by Mizuho’s Irina Koffler. The larger packaging has helped boost sales volumes, Koffler said.
- Barrons.com•23 days ago
Valeant: It's More Than Just Dermatology
Shares of Valeant Pharmaceuticals International (VRX) sold off earlier this month after the company received a Complete Response Letter from the Food and Drug Administration concerning its plaque psoriasis Duobrii. However, Mizuho's Irina Koffler argues that the selloff is overdone, as she believes that Xifaxan, the traveler's diarrhea and irritable-bowel-syndrome treatment, is Valeant's key growth driver, rather than its dermatology portfolio. She reiterated a Buy rating on Valeant Friday and raised her price target by $4 to $31. The SPDR S&P Pharmaceuticals ETF (XPH) is up 0.5% to $43.18 and the Health Care Select Sector SPDR ETF (XLV) is up 0.8% to $83.92.
- Market Realist•24 days ago
Why Has Valeant Stock Fallen in June?
Valeant Pharmaceuticals (VRX) stock has been falling in June. Valeant’s division Ortho Dermatologics received a CRL (complete response letter) from the FDA on June 18 for its new drug application for Duobril, which treats plaque psoriasis. Valeant’s Siliq, which treats moderate to severe psoriasis, received FDA approval earlier.
- ACCESSWIRE•24 days ago
Complimentary Technical Snapshots on Valeant Pharmaceuticals International and Three More Healthcare Stocks
Stock Research Monitor: QTNT, ADMP, and PETS LONDON, UK / ACCESSWIRE / June 28, 2018 / If you want a free Stock Review on VRX sign up now at www.wallstequities.com/registration . On Wednesday, June 27, ...
- Barrons.com•25 days ago
A Win for Valeant: Treatment to Aid Opioid Addiction
By now, we've all heard of the horrors of the U.S. opioid crisis: Well over 100 people a day die by opioid overdose, and a quarter of all patients who are prescribed opioids for chronic pain–11.5 million people–end up misusing the medications. Valeant is off 0.5% to $23.19 this morning.
- PR Newswire•26 days ago
Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine)
Salix Sales Force to Begin Promoting LUCEMYRA to Primary Care and Pain Management Physicians LUCEMYRA is the First and Only Non-Opioid Medication Approved for Mitigation of Opioid Withdrawal Symptoms LOUISVILLE, ...
- ACCESSWIRE•29 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valeant Pharmaceuticals International, Inc. - VRX
NEW YORK, NY / ACCESSWIRE / June 23, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company") (VRX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The investigation concerns whether Valeant and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- CNBC•last month
Cramer's lightning round: I don't like Snap's ownership structure
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a much debated social media play.
- CNBC•last month
The woman behind 'female Viagra' sold her company for $1 billion — then got it back for free
Cindy Eckert is the anti-Martin Shkreli — after the billion-dollar Valeant debacle, the founder of Sprout Pharmaceuticals is back as CEO and she's slashed the price of the little pink libido pill for women. Here's what she learned from the experience and where she goes from here.
- PR Newswire•last month
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valeant Pharmaceuticals International, Inc. - VRX
NEW YORK , June 19, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company") (NYSE: VRX). ...
- PR Newswire•last month
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Valeant Pharmaceuticals International, Inc. (VRX)
NEW YORK , June 19, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Valeant Pharmaceuticals International, Inc. ...
- Zacks•last month
Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis
Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.
- Barrons.com•last month
Valeant's FDA Letter: Don't Write Off the Stock Yet
Shares of Valeant Pharmaceuticals International (VRX) started the week off on a down note, on news that the company received a Complete Response Letter from the Food and Drug Administration concerning its plaque psoriasis treatment Monday, and the shares are falling again today. Cantor Fitzgerald argued that the letter wasn't anything for investors to worry about, and today H.C. Wainwright analyst Raghuram Selvaraju argues much the same thing, even if he has a Neutral rating on the stock. Selvaraju writes that although the psoriasis drug, Duobrii, was one of the "Significant Seven" products around which he saw the "new" Valeant would be built, he--much like Cantor--hasn't included sales from the treatment in his model for 2018.
